Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05784441 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
A Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 15
- Study locations
NCT05784441 is a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 21 participants, below the 27-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (22% lower). The trial reports 15 study locations across 8 states.
The verdict
NCT05784441, a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 15
- Study locations
Study Summary
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Conditions Studied
Interventions
- DRUG JNJ-90009530
Study Locations (15)
Other
- Royal Prince Alfred Hospital - Camperdown
- Monash Medical Centre - Clayton
- Austin Hospital - Heidelberg
- Royal Brisbane and Women's Hospital - Herston
- Westmead Hospital - Westmead
- Hadassah Medical Center - Jerusalem
- Sheba Medical Center - Ramat Gan
- University College London Hospitals - London
Iowa
- University of Iowa Hospital - Iowa City
Kentucky
- University of Kentucky - Lexington
Minnesota
- Mayo Clinic Rochester - Rochester
New Jersey
- Rutgers University - New Brunswick
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2040-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05784441
The ClinicalTrials.gov registry entry for NCT05784441 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 27-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (22% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which JNJ-90009530 is the first listed.
NCT05784441 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Other, Iowa, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05784441 about?
NCT05784441 is a clinical study titled "A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)". The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a re...
What is the current status of trial NCT05784441?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-11-06. Estimated completion is 2040-01-03.
What conditions does trial NCT05784441 study?
This clinical trial studies the following conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05784441?
The interventions under investigation include: JNJ-90009530 (DRUG).
Who is sponsoring clinical trial NCT05784441?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05784441 being conducted?
This trial has 15 study locations across Iowa, Kentucky, Minnesota, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RECRUITING · Phase 1
-
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.